WATER III Trial

Aquablation vs. Laser Enucleation for Large Prostates

  • Study Title: WATER III: Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80–180 mL80\text{--}180\,\text{mL}) in Benign Prostatic Hyperplasia

  • Citation: Ritter et al., 2025 European Association of Urology (EAU) Abstract Presentation

  • Sponsor / Document ID: ML0738.A | © 2025 PROCEPT BioRobotics Corporation

  • Primary Objective: Determine safety and efficacy outcomes comparing Aquablation therapy against transurethral laser enucleation of the prostate (LEP) for the treatment of large prostates (80–180 mL80\text{--}180\,\text{mL})

Study Design and Methodology

  • Trial Classification: Investigator-initiated, prospective, randomized and non-randomized trial

  • Clinical Study Locations: Conducted across 55 study centers located in Germany and the United Kingdom

  • Prostate Volume Inclusion Criteria: Prostates ranging from 80 mL80\,\text{mL} to 180 mL180\,\text{mL}

  • Patient Arms and Sample Sizes:

    • Aquablation Therapy Arm: n=98n = 98 patients

    • Laser Enucleation of the Prostate (LEP) Arm: n=88n = 88 patients

  • Long-Term Durability Plan: Planned follow-up period extending to 5 years5\,\text{years}

Primary Endpoints

  • Primary Efficacy Endpoint: Reduction in International Prostate Symptom Score (IPSS)

  • Primary Safety Endpoint:

    • Occurrence of Clavien-Dindo (CD) grade ≥2\ge 2 adverse events

    • Persistent Clavien-Dindo (CD) grade 11 adverse events, specifically including ejaculatory dysfunction, erectile dysfunction, or urinary incontinence

Key Efficacy and Safety Results at 3 Months

  • Efficacy Outcomes (IPSS Symptom Reduction):

    • Aquablation Therapy: IPSS reduction of 2020 points

    • LEP Group: IPSS reduction of 2222 points

  • Functional Outcomes (Peak Urinary Flow Rate / Qmax):

    • Aquablation Therapy: Peak flow increased from 9 mL/sec9\,\text{mL/sec} at baseline to 20 mL/sec20\,\text{mL/sec} at 3 months3\,\text{months} (representing an 11 mL/sec11\,\text{mL/sec} improvement)

    • LEP Group: Peak flow increased from 11 mL/sec11\,\text{mL/sec} at baseline to 28 mL/sec28\,\text{mL/sec} at 3 months3\,\text{months}

  • Post-Void Residual (PVR): No significant difference between Aquablation therapy and LEP in PVR reduction

  • Ejaculatory Dysfunction (evaluated in sexually active patients only):

    • Aquablation Therapy: 14.8%14.8\%

    • LEP Group: 77.1%77.1\%

  • Stress Urinary Incontinence (evaluated in patients who were pad-free at baseline):

    • Aquablation Therapy: 0%0\%

    • LEP Group: 9.1%9.1\%

  • Postoperative Complications and Interventions:

    • Blood Transfusion Rate: Aquablation 0%0\% vs. LEP 2.3%2.3\%

    • Surgical Takeback Rate: Aquablation 5.1%5.1\% vs. LEP 3.4%3.4\%

  • Retreatment Rates: 0%0\% retreatments reported for both treatment modalities at 3 months3\,\text{months}

Author Conclusions and Clinical Findings

  • Comparative Short-Term Outcomes:

    • Aquablation therapy and LEP showed no significant difference in short-term IPSS symptom improvement, bleeding risk, and PVR reduction.

  • Laser Enucleation (LEP) Superiority Domains:

    • LEP demonstrated superiority over Aquablation therapy in achieving greater prostate volume reduction and higher improvements in peak urinary flow rate (Qmax\text{Qmax}).

  • Aquablation Therapy Superiority Domains:

    • Aquablation therapy demonstrated superiority over LEP by maintaining lower rates of ejaculatory dysfunction and reducing the incidence of stress urinary incontinence.